Document is current
Any future updates will be listed below
-
Authors
Oh, Wonsuk
Veshtaj, Marinela
Sawant, Ashwin
Agrawal, Pulkit
Gomez, Hernando
Suarez-Farinas, Mayte
Oropello, John
Kohli-Seth, Roopa
Kashani, Kianoush
Kellum, John A.
Nadkarni, Girish
Sakhuja, Ankit
-
Funding
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (K08DK131286)
- License Information
-
More Information
Article History
Received: 18 January 2025
Accepted: 10 May 2025
First Online: 26 May 2025
Declarations
:
: The study received approval from the Institutional Review Board at the Icahn School of Medicine at Mount Sinai (approval no. 19–00951).
: Not applicable.
: GNN is a founder of Renalytix, Pensieve, Verici and provides consultancy services to AstraZeneca, Reata, Renalytix, Siemens Healthineer and Variant Bio, serves a scientific advisory board member for Renalytix and Pensieve. He also has equity in Renalytix, Pensieve and Verici. JAK reports receiving consulting fees from Astute Medical/bioMerieux, Astellas, Alexion, Chugai Pharma, Novartis, Mitsubishi Tenabe and GE Healthcare and is a Full-time employee of Spectral Medical. All remaining authors have declared no conflicts of interest.
